
SXTP Stock Forecast & Price Target
SXTP Analyst Ratings
Bulls say
60 Degrees Pharmaceuticals Inc has demonstrated impressive financial growth, with net product revenues increasing 140% to $607.6k in FY24 and a remarkable 223% increase in Q3 FY25 revenue year-over-year, reflecting strong demand for its product ARAKODA. The continued growth in ARAKODA deliveries, rising by 14% to 1,505 boxes in Q3 FY25, highlights the increasing market acceptance and potential for sustained revenue expansion. Furthermore, the favorable safety profile of tafenoquine presents opportunities for broader therapeutic applications, enhancing the company's commercialization prospects in the competitive pharmaceutical landscape.
Bears say
60 Degrees Pharmaceuticals Inc faces significant challenges reflected in its current financial performance, as evidenced by a reported gross loss of approximately $9,000 in Q3 FY24, which marks a concerning decline from a gross profit of $36,000 in the previous quarter, primarily due to a one-time inventory write-off. The firm's forward multiples are depressed amidst market volatility, compounded by low visibility on regulatory approvals and risks of dilution from future financing, creating an uncertain outlook for cash flow and profitability. Additionally, the company is exposed to commercial risks due to diminishing demand and potential market share loss, as evidenced by the emerging resistance to artemisinin treatments, which could further threaten the viability of its product pipeline.
This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
SXTP Analyst Forecast & Price Prediction
Start investing in SXTP
Order type
Buy in
Order amount
Est. shares
0 shares